Apatinib Mesylate Plus Anti-PD1 Therapy (SHR-1210) in Locally Advanced, Unresectable or Metastatic Osteosarcoma(APFAO)Refractory to Chemotherapy : a Single Institution, Open-label, Phase 2 Trial
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- Acronyms APFAO
- 04 Jun 2019 Results assessing activity of apatinib in combination with camrelizumab in patients with inoperable high-grade osteosarcoma progressing after chemotherapy presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 11 Mar 2019 Planned End Date changed from 1 Mar 2020 to 15 Mar 2020.
- 02 Sep 2018 Status changed from recruiting to active, no longer recruiting.